OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
Tanvi Verma, Nikolaos Papadantonakis, Deniz Peker Barclift, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 514-514
Open Access | Times Cited: 5
Tanvi Verma, Nikolaos Papadantonakis, Deniz Peker Barclift, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 514-514
Open Access | Times Cited: 5
Showing 5 citing articles:
Study of mutation profile in myelofibrosis and response to low dose ruxolitinib: a tertiary care experience
D Abinaya, Aruna Rajendran, Divya Manoharan, et al.
International Journal of Advances in Medicine (2025)
Open Access
D Abinaya, Aruna Rajendran, Divya Manoharan, et al.
International Journal of Advances in Medicine (2025)
Open Access
Selinexor plus ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis: SENTRY Phase 3 study design
John O. Mascarenhas, Keri Maher, Raajit K. Rampal, et al.
Future Oncology (2025), pp. 1-7
Open Access
John O. Mascarenhas, Keri Maher, Raajit K. Rampal, et al.
Future Oncology (2025), pp. 1-7
Open Access
Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs
Chaoyi Wei, Hein Than, Feng‐Ju Huang, et al.
Hematological Oncology (2025) Vol. 43, Iss. S1
Open Access
Chaoyi Wei, Hein Than, Feng‐Ju Huang, et al.
Hematological Oncology (2025) Vol. 43, Iss. S1
Open Access
TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment
Linsheng Zhang, Brooj Abro, Andrew T. Campbell, et al.
Laboratory Medicine (2024) Vol. 55, Iss. 6, pp. 686-699
Open Access | Times Cited: 3
Linsheng Zhang, Brooj Abro, Andrew T. Campbell, et al.
Laboratory Medicine (2024) Vol. 55, Iss. 6, pp. 686-699
Open Access | Times Cited: 3
Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
Olga Vinogradova, M. M. Pankraskina, А. Л. Неверова, et al.
Oncohematology (2024) Vol. 19, Iss. 3, pp. 16-33
Open Access | Times Cited: 1
Olga Vinogradova, M. M. Pankraskina, А. Л. Неверова, et al.
Oncohematology (2024) Vol. 19, Iss. 3, pp. 16-33
Open Access | Times Cited: 1
Clinical features and treatment of newly diagnosed multiple myeloma with secondary myelofibrosis: a retrospective study
Han Xu, Yu-Jie Xu, Mengying Wang, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access
Han Xu, Yu-Jie Xu, Mengying Wang, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access
